Home / Technology & Devices (page 2)

Technology & Devices

Natera Announces Publication of Analytical Validation Study Demonstrating Superior Precision of Its Kidney Transplant Rejection Assay

SAN CARLOS, Calif., Feb. 22, 2019 /PRNewswire/ –Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced analytical validation study results to be published online in the journal  Transplantation demonstrating the superior performance of its donor-derived cell-free DNA (dd-cfDNA) test for detecting active rejection in kidney transplant recipients.1 The study showed superior assay …

Read More »

Gamida Cell and Editas Medicine Partner to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, to evaluate the potential use of Editas Medicine’s CRISPR technology to edit NAM-NK cells, which are natural killer cells that have been expanded using Gamida …

Read More »

Medtronic Receives FDA Breakthrough Designation for Developing Personalized Closed Loop Insulin Pump System for Diabetes Management

DUBLIN – February 19, 2019 – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Personalized Closed Loop (PCL) insulin pump system, currently in development. The PCL technology is designed to automate insulin …

Read More »

Novartis Enters 10-Target Antibody Discovery Deal with AbCellera

VANCOUVER, British Columbia–(BUSINESS WIRE)–AbCellera, a technology leader in therapeutic antibody discovery from natural immune repertoires, today announced a multi-target and multi-year collaboration with Novartis. Under the agreement, AbCellera will apply its expertise in antibody discovery and its single-cell screening technology to advance programs on up to ten targets elected by …

Read More »

Amgen Enters Multi-Target Collaboration with Abilita Bio for its Membrane Protein Technology

SAN DIEGO, Feb. 13, 2019 /PRNewswire/ — Abilita Bio, Inc. announced today that it has entered into a multi-target research collaboration agreement with Amgen, a world leader in biotechnology. Under the terms of the agreement, Abilita Bio will leverage its proprietary Enabled Membrane Protein (EMP™) technology platform to support Amgen’s …

Read More »

Johnson & Johnson to Acquire Robotic Surgery Company Auris Health for $3.4 Billion

New Brunswick, NJ – February 13, 2019 – Focused on creating the next frontier of surgery, Johnson & Johnson (NYSE: JNJ), today announced that Ethicon, Inc., entered into a definitive agreement to acquire Auris Health, Inc. for approximately $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, in the aggregate, …

Read More »

Boehringer Ingelheim and IBM Collaborate to Explore Use of Blockchain Technology in Clinical Trials

BURLINGTON, Ontario and MARKHAM, Ontario, Feb. 12, 2019 /PRNewswire/ — Boehringer Ingelheim (Canada) Ltd. and IBM Canada (NYSE: IBM) announced today at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology in clinical trials. This collaboration underscores Boehringer …

Read More »

FDA Approves Grifols’ Procleix Babesia Assay for Donor Screening on Procleix Panther System

BARCELONA, Spain, Feb. 7, 2019 /PRNewswire/ — Grifols, a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, announced today that the U.S. Food and Drug Administration (FDA) approved the Procleix Babesia assay, a qualitative assay for the detection of the ribosomal RNA …

Read More »

Newly Published Study Shows DecisionDx-Melanoma Prognostic Test Accurately Identified Risk for Patients with Melanoma of the Head and Neck

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer management decisions, today announced the publication of a study highlighting the ability of the DecisionDx®-Melanoma test to accurately determine risk of metastasis in patients with melanoma of the head and neck. Results from …

Read More »

Argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE Technology

Breda, the Netherlands / Ghent, Belgium & San Diego – argenx (Euronext & Nasdaq: ARGX) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that enables use by argenx of Halozyme’s ENHANZE® drug delivery technology to develop multiple subcutaneous product formulations for current or future argenx …

Read More »